Zemplar

Hyperparathyroidism, Secondary, Hyperparathyroidism, Secondary, Renal Insufficiency, Chronic + 1 more

Treatment

8 FDA approvals

10 Active Studies for Zemplar

Treatment for

Hyperparathyroidism, Secondary

What is Zemplar

ParicalcitolThe Generic name of this drug

Treatment SummaryParicalcitol is a synthetic form of vitamin D. It is used to lower levels of parathyroid hormone in patients with chronic kidney disease. This medication helps to prevent and treat high levels of parathyroid hormone caused by kidney failure.

Zemplaris the brand name

image of different drug pills on a surface

Zemplar Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zemplar

Paricalcitol

1998

Approved as Treatment by the FDA

Paricalcitol, also known as Zemplar, is approved by the FDA for 8 uses which include Hyperparathyroidism, Secondary and Hyperparathyroidism, Secondary .

Hyperparathyroidism, Secondary

Renal Insufficiency, Chronic

Chronic Kidney Disease, Stage 3 (Moderate)

Secondary Hyperparathyroidism (SHPT)

Stage 4 Chronic Kidney Disease

Stage 5 Chronic Kidney Disease (CKD)

prophylaxis of secondary hyperparathyroidism

Effectiveness

How Zemplar Affects PatientsSecondary hyperparathyroidism is caused by a lack of vitamin D in the body, which is usually made naturally in the skin and obtained from diet. Vitamin D needs to go through two processes in the liver and kidney to be activated, and this is done by a hormone called calcitriol. Without enough calcitriol, the parathyroid gland, intestine, kidney, and bone cannot keep calcium and phosphorus in balance. This causes secondary hyperparathyroidism, which affects bone turnover and can cause renal osteodystrophy. Paricalcitol is a medication used to treat secondary hyperparathyroidism and it has been

How Zemplar works in the bodyParicalcitol is a synthetic form of vitamin D. It works by binding to a protein in the body, called the Vitamin D Receptor (VDR). This causes other proteins in the body to work differently, including reducing the amount of Parathyroid Hormone (PTH) in the body. PTH normally increases the amount of calcium in the blood, which can be harmful if it gets too high.

When to interrupt dosage

The recommended measure of Zemplar depends on the diagnosed condition, including Hyperparathyroidism, Secondary, Hemodialysis and Stage 4 Chronic Kidney Disease. The dosage can be found in the table below, contingent upon the technique of administration.

Condition

Dosage

Administration

Hyperparathyroidism, Secondary

, 0.005 mg/mL, 0.002 mg/mL, 0.001 mg, 0.002 mg, 0.004 mg, 1.0 mg, 2.0 mg, 4.0 mg, 0.01 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous

Renal Insufficiency, Chronic

, 0.005 mg/mL, 0.002 mg/mL, 0.001 mg, 0.002 mg, 0.004 mg, 1.0 mg, 2.0 mg, 4.0 mg, 0.01 mg/mL

Hyperparathyroidism, Secondary

, 0.005 mg/mL, 0.002 mg/mL, 0.001 mg, 0.002 mg, 0.004 mg, 1.0 mg, 2.0 mg, 4.0 mg, 0.01 mg/mL

Stage 4 Chronic Kidney Disease

, 0.005 mg/mL, 0.002 mg/mL, 0.001 mg, 0.002 mg, 0.004 mg, 1.0 mg, 2.0 mg, 4.0 mg, 0.01 mg/mL

Warnings

There are 20 known major drug interactions with Zemplar.

Common Zemplar Drug Interactions

Drug Name

Risk Level

Description

Sucralfate

Major

The serum concentration of Sucralfate can be increased when it is combined with Paricalcitol.

1alpha,24S-Dihydroxyvitamin D2

Moderate

The risk or severity of adverse effects can be increased when Paricalcitol is combined with 1alpha,24S-Dihydroxyvitamin D2.

1alpha-Hydroxyvitamin D5

Moderate

The risk or severity of adverse effects can be increased when Paricalcitol is combined with 1alpha-Hydroxyvitamin D5.

Acetyldigitoxin

Moderate

The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Acetyldigitoxin.

Acetyldigoxin

Moderate

The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Acetyldigoxin.

image of a doctor in a lab doing drug, clinical research

Zemplar Novel Uses: Which Conditions Have a Clinical Trial Featuring Zemplar?

15 active trials are currently evaluating the potential of Zemplar in alleviating Stage 4 Chronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate) and Hemodialysis.

Condition

Clinical Trials

Trial Phases

Renal Insufficiency, Chronic

3 Actively Recruiting

Phase 2, Phase 1, Not Applicable

Hyperparathyroidism, Secondary

2 Actively Recruiting

Phase 3, Not Applicable

Hyperparathyroidism, Secondary

0 Actively Recruiting

Stage 4 Chronic Kidney Disease

6 Actively Recruiting

Phase 4, Phase 1, Phase 2, Not Applicable